The role of dapagliflozin in the management of heart failure: an update on the emerging evidence
The burden and cost of heart failure management, primarily in the form of hospitalization in
the setting of decompensated heart failure, continue to be some of the biggest clinical …
the setting of decompensated heart failure, continue to be some of the biggest clinical …
Dapagliflozin: a review in symptomatic heart failure with reduced ejection fraction
HA Blair - American Journal of Cardiovascular Drugs, 2021 - Springer
Abstract Dapagliflozin [Farxiga®(USA); Forxiga®(EU)], a sodium–glucose cotransporter 2
(SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults …
(SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults …
Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney …
H Yanai, H Adachi, M Hakoshima, H Katsuyama - Metabolites, 2023 - mdpi.com
Beyond lowering plasma glucose levels, sodium–glucose cotransporter 2 inhibitors
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
[HTML][HTML] Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience
L Islam, D Jose, M Alkhalifah, D Blaibel… - World Journal of …, 2024 - ncbi.nlm.nih.gov
BACKGROUND Sodium glucose cotransporter-2 inhibitors (SGLT-2i) are a class of drugs
with modest antidiabetic efficacy, weight loss effect, and cardiovascular benefits as proven …
with modest antidiabetic efficacy, weight loss effect, and cardiovascular benefits as proven …
[HTML][HTML] Comparative efficacy of dapagliflozin and empagliflozin of a fixed dose in heart failure: a network meta-analysis
Z Shi, F Gao, W Liu, X He - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Background: The efficacy of dapagliflozin and empagliflozin in Sodium-glucose Cotransport-
2 Inhibitors (SGLT-2i) in patients with heart failure (HF) has been discovered. However …
2 Inhibitors (SGLT-2i) in patients with heart failure (HF) has been discovered. However …
The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials
HB Chen, RS Meng, YL Yang, TH Yu - Expert Opinion on Drug …, 2023 - Taylor & Francis
Background Dapagliflozin has proven cardioprotective and nephroprotective effects.
However, the risk of all-cause death with dapagliflozin remains unclear. Research design …
However, the risk of all-cause death with dapagliflozin remains unclear. Research design …
Safety of sodium‐glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta‐analysis
H Soleimani, B Saeedian, Y Pasebani… - ESC Heart …, 2024 - Wiley Online Library
Abstract Sodium–glucose cotransporter‐2 inhibitors (SGLT2is) reduce morbidity and
mortality for heart failure (HF) patients and are recommended as cornerstones for their …
mortality for heart failure (HF) patients and are recommended as cornerstones for their …
Adverse events and drug–drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure
C Stöllberger, J Finsterer… - Expert Review of …, 2023 - Taylor & Francis
Introduction Sodium glucose co-transporter 2-inhibitors (SGLT2-I), antihyperglycemic
agents, are increasingly prescribed in chronic heart failure (CHF). Their risk for drug–drug …
agents, are increasingly prescribed in chronic heart failure (CHF). Their risk for drug–drug …
Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews
A Sephien, M Ghobrial, T Reljic, X Prida… - International Journal of …, 2023 - Elsevier
Aims Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to have benefit
in patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SRs and …
in patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SRs and …
Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis
L Jiang, Y Jia, X Wang, Z Wang, X Lv, Y Jia… - Expert Opinion on …, 2023 - Taylor & Francis
Background This study aimed to evaluate the efficacy and safety of dapagliflozin as a
monotherapy glucose-lowering drug treatment for older adults with diabetes. Research …
monotherapy glucose-lowering drug treatment for older adults with diabetes. Research …